The same group completed a similar phase II trial investigating the effects of anti-progestin ulipristal acetate (5 mg daily) on surrogate markers of breast cancer risk in high-risk premenopausal women (BRCA1/2 mutation carriers or high lifetime risk by assessment models; NCT02408770). This evidence concerns the gene BRCA1 and breast carcinoma.